Please login to the form below

Not currently logged in
Email:
Password:

immuno-oncology

This page shows the latest immuno-oncology news and features for those working in and with pharma, biotech and healthcare.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer

This follows US approval last year, and is the first Immuno-Oncology (IO) combination therapy for patients with this type of cancer in the European Union. ... which underscores the need for new treatments for this disease,” said Bernard Escudier, MD, ex

Latest news

  • Chinese biotechs aim PD-L1 antibody at hepatitis B Chinese biotechs aim PD-L1 antibody at hepatitis B

    Front-runners in the immuno-oncology category such as Bristol-Myers Squibb (BMS) with Opdivo (nivolumab) and Merck &Co/MSD with Keytruda (pembrolizumab) have not started trialling their blockbuster drugs in

  • Moderna CEO makes case for firm’s lofty valuation Moderna CEO makes case for firm’s lofty valuation

    Moderna's CEO Stéphane Bancel. From its inception eight years ago, it now has 21 development programmes spanning prophylactic vaccines, cancer vaccines, immuno-oncology, and others, with 11 already in trials. ... Other new studies coming up are phase 1

  • Nektar confirms BMS deal for NKTR-214 is on track Nektar confirms BMS deal for NKTR-214 is on track

    Nektar Therapeutics has said the company’s $3.6bn deal with Bristol-Myers Squibb for immuno-oncology drug NKTR-214 won’t be affected by the big pharma’s acquisition of ... Almost forgotten among the interest in Nektar’s immuno-oncology pipeline

  • Sanofi and Regeneron re-jig immuno-oncology deal Sanofi and Regeneron re-jig immuno-oncology deal

    Partners refocus around two promising bispecific candidates. Sanofi has updated its $2.17bn immuno-oncology deal with long-term partner Regeneron, refocusing the alliance around two promising bispecific antibody candidates. ... Sanofi will pay Regeneron

  • Lilly adds to pharma M&A run with $8bn Loxo buy-out Lilly adds to pharma M&A run with $8bn Loxo buy-out

    Lilly claims company ahead of more dominant oncology players. After the excitement caused by the $74bn acquisition of Celgene by BMS last week, Lilly has snapped up immunotherapy pioneers Loxo Therapeutics ... platforms. Acquiring Loxo will help Lilly

More from news
Approximately 66 fully matching, plus 252 partially matching documents found.

Latest Intelligence

  • Is China ready for a pharmaceutical gold rush?

    China has long been a leader in pharmaceutical manufacturing and export.But with the news that the country has approved its first immuno- oncology (I-O) treatment comes the hope that ... Professor Yi-Long Wu, a tenured director of Guangdong General

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Imfinzi, competing in the hypercompetitive world of immuno-oncology, was developed by MedImmune, the company’s US-based biologics research division, while the two small molecule drugs were developed in the ... So that’s the rationale behind

  • Deal Watch October 2018

    Roche will pay up to $759m for its acquisition of Tusk Therapeutics, a UK‐based company which develops immuno-oncology treatments. ... Acquisition. $2B. Tango Therapeutics/. Gilead Sciences. Pipeline of up to 5 targeted immuno‐oncology.

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    therapy areas, most especially oncology, and expansion in China are two of the established tactics which he looks set to pursue. ... However in the most valuable sub-sector of the market, immuno-oncology, the company is struggling to make major inroads.

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    MRC scientists are welcome to work in the building and our oncology staff are working in the CRUK Institute. ... revenues in its oncology division grew by 42% in the first half of this year, with chief executive Pascal Soriot claiming the company was

More from intelligence
Approximately 3 fully matching, plus 49 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 18 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics